Cromos Pharma

AI is no longer viewed simply as a tool for operational efficiency in clinical trials.

The FDA is increasingly positioning AI as part of the clinical development infrastructure itself, with growing focus on governance, oversight, transparency, and regulatory trust.
In this article, we explore what the FDA’s recent initiatives could mean for the future of clinical research and why the industry may be entering a new phase of AI adoption.

Read more: https://cromospharma.com/fda-ai-and-the-future-of-clinical-trials/

Poland is no longer just a cost-driven clinical research destination.

With strong oncology patient access, experienced investigators, growing infrastructure, and increasing operational maturity, the country is becoming a strategic market for European oncology trials.

In this article, Magda Klosowska, Regional Clinical Manager for Europe at Cromos Pharma, shares why sponsors should rethink Poland’s role in oncology clinical development.

Read more: https://cromospharma.com/cro-in-poland-why-poland-is-becoming-a-core-country-for-oncology-clinical-trials-in-europe/

On World Clinical Trials Day, the conversation is no longer only about innovation.

As clinical trials become more complex across operations, technology, patient recruitment, and site management, the industry is facing a new challenge: not just developing therapies, but delivering trials efficiently at scale.

In our latest article, we explore the key trends shaping clinical research in 2026. Read more: https://cromospharma.com/world-clinical-trials-day-clinical-research-is-not-where-it-used-to-be/?preview_id=11753&preview_nonce=c21d76b9e3&_thumbnail_id=11754&preview=true

The recent US–UK pharmaceutical agreement may be about far more than drug pricing.

Pharma is increasingly becoming part of trade strategy, industrial policy, and geopolitical competition. As global powers compete for innovation, investment, and manufacturing leadership, the rules shaping the industry may be changing faster than many realize.

Read more:https://cromospharma.com/the-us-uk-pharma-deal-is-bigger-than-it-looks/

In the latest edition of Cromos Pharma’s Newsletter, we highlight key developments shaping clinical research in 2026:

– FDA Transparency Pressure: More than 2,200 sponsors were flagged over missing trial results, highlighting growing scrutiny around data reporting and clinical transparency.
– Rare Disease Innovation: EMA recommended approval of plozasiran, a first in class siRNA therapy for familial chylomicronaemia syndrome with significant reductions in triglycerides and pancreatitis risk.
– A Potential Breakthrough in Pancreatic Cancer: Daraxonrasib Phase III data demonstrated one of the most meaningful survival advances seen in pancreatic cancer in decades.

Read the full newsletter: https://cromospharma.com/clinical-research-focus-52nd-edition/